Vertex Pharmaceuticals (VRTX) Assets Average (2010 - 2026)

Vertex Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $26.1 billion for Q1 2026.

• In Q1 2026, Assets Average rose 14.78% year-over-year to $26.1 billion; the TTM figure through Mar 2026 stood at $26.1 billion (up 14.78% YoY), while the FY2025 annual figure was $24.1 billion, up 6.44% from the prior year.
• Assets Average was $26.1 billion for Q1 2026 at Vertex Pharmaceuticals, up from $25.3 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $26.1 billion in Q1 2026 to a low of $13.8 billion in Q1 2022.
• Historically, Assets Average has averaged $20.9 billion across 5 years, with a median of $22.0 billion in 2024.
• The sharpest annual moves came in 2023 and 2025: Assets Average soared 34.08% in 2023, then declined 2.65% in 2025.
• A 5-year view of Assets Average shows it stood at $17.4 billion in 2022, then gained by 27.54% to $22.2 billion in 2023, then increased by 0.71% to $22.4 billion in 2024, then advanced by 12.8% to $25.3 billion in 2025, then grew by 3.21% to $26.1 billion in 2026.
• The last three Assets Average figures came in at $26.1 billion (Q1 2026), $25.3 billion (Q4 2025), and $24.4 billion (Q3 2025), per Business Quant data.